Working with TipRanks
Follow Us
Stocks
ETFs
Options
Commodities
Crypto
Currency
Pro Newsletters
Research Tools
Calendars
Economic Indicators
Class Actions
Calculators
Education
About Us
Working with TipRanks
Follow Us
Rahul Singhvi Insider Profile
4 Followers
Rahul Singhvi, Director at ImmunoCellular Therapeutics, holds 96.07K shares in Codexis (Ticker: CDXS), holds 15.00K shares in ImmunoCellular Therapeutics (Ticker: IMUC), holds 113.10K shares in Novavax (Ticker: NVAX).
Rahul Singhvi has not reported sufficient informative transactions and therefore cannot be ranked.
Time Frame
Compare to
Insider Holdings
Insider Roles
Roles that Rahul Singhvi holds in companies
Most Profitable Insider Trade
The most profitable trade made by Rahul Singhvi
Rahul Singhvi's Trading History
ImmunoCellular Therapeutics
Sep 22, 2015
Director
Uninformative Buy
―
$1.73K
Codexis
Jun 13, 2024
Director
Uninformative Buy
―
$391.96K
Novavax
Jul 01, 2009
President & CEO, Director
Informative Sell
772.86K
$1.01M
List of latest transactions for each holding click on a transaction to see Rahul Singhvi's performance on stock
You May Also Like
Rahul Singhvi insider profile FAQ
What is the percentage of profitable transactions made by Rahul Singhvi?
The percentage of profitable transactions made by Rahul Singhvi is ―.
What is the average return per transaction made by Rahul Singhvi?
The average return per transaction made by Rahul Singhvi is ―.
What stocks does Rahul Singhvi hold?
Rahul Singhvi holds: IMUC, CDXS, NVAX stocks.
What was Rahul Singhvi’s latest transaction?
Rahul Singhvi latest transaction was an Uninformative Buy of ―.
What was Rahul Singhvi's most profitable transaction?
Rahul Singhvi’s most profitable transaction was an Informative Sell of NVAX stock on July 1, 2009. The return on the trade was 27.40%.
What is Rahul Singhvi's role in ImmunoCellular Therapeutics?
Rahul Singhvi's role in ImmunoCellular Therapeutics is Director.
How can I follow the stock ratings of top corporate insiders?
Head over to our Expert Center to see a list of the Top 100 corporate insiders and follow the corporate insiders of your choice. Visit their profiles for more details about their stock transactions and see how they perform on a stock-by-stock basis.